|
|
Article: Third Time's Not A Charm Encysive Tanks On Third PAH Approvable Letter For Thelin.
- Article from:
- BIOWORLD Today
- Article date:
- June 19, 2007
- Author:
CopyrightCOPYRIGHT 2007 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Trista Morrison, Staff Writer
Shares of Encysive Pharmaceuticals Inc. fell 43.4 percent after the Houston-based company received its third approvable letter for Thelin (sitaxsentan sodium) 100 mg tablets in the treatment of pulmonary arterial hypertension (PAH).
President and CEO Bruce Given said in a Monday morning conference call that the company is "moving to formal dispute resolution" with the FDA. At issue, according to Given, is whether the special protocol assessment (SPA) agreed upon by both parties for a Phase III trial called STRIDE-2 is binding.
The new drug application filing for Thelin was based on data from two randomized, ...